| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cyclooxygenase-II (COX-2; PTGS2). Tazofelone is a selective inhibitor of COX-2, the isoform of cyclooxygenase induced by inflammatory stimuli. By blocking COX-2, it reduces the production of pro-inflammatory prostaglandins (PGE2) in inflamed tissues, while sparing the constitutively expressed COX-1 in the gastric mucosa to minimize gastrointestinal side effects.
|
|---|---|
| ln Vitro |
In vitro, Tazofelone (LY 213829) is a cyclooxygenase-II (COX-2) inhibitor. It selectively inhibits COX-2 enzymatic activity, blocking the conversion of arachidonic acid to prostaglandin H2, the precursor of pro-inflammatory prostaglandins such as PGE2. At concentrations that inhibit COX-2, it has minimal effect on COX-1. The conversion of Tazofelone to its sulfoxide and quinoline metabolites is primarily mediated by cytochrome P450 3A (CYP3A).
|
| ln Vivo |
No detailed in vivo studies for Tazofelone are publicly available in modern literature. As a COX-2 selective inhibitor, it would be expected to reduce colonic inflammation in animal models of inflammatory bowel disease (e.g., DSS-induced colitis or TNBS-induced colitis) by reducing prostaglandin E2 levels in the intestinal mucosa. It may also show reduced gastrointestinal ulcerogenicity compared to non-selective NSAIDs.
|
| Enzyme Assay |
A COX inhibition assay is performed using purified human recombinant COX-1 and COX-2 enzymes. The enzymes are pre-incubated with serially diluted Tazofelone (0.1-1000 uM) for 10 minutes at room temperature. Arachidonic acid (100 uM) is then added, and the reaction proceeds for 2 minutes at 37degC. The reaction is stopped with 1 M HCl, and PGE2 production is quantified by ELISA. The IC50 values for COX-1 and COX-2 are calculated to determine selectivity.
|
| Cell Assay |
For in vitro cellular assays, human whole blood is collected from healthy volunteers. For COX-1 activity, blood is allowed to clot at 37degC for 1 hour in the presence of serially diluted Tazofelone (0.1-1000 uM), and serum TXB2 levels are measured by ELISA. For COX-2 activity, blood is treated with lipopolysaccharide (LPS, 10 ug/mL) and incubated with Tazofelone for 24 hours, and plasma PGE2 levels are measured by ELISA. Cell viability is assessed using trypan blue exclusion.
|
| Animal Protocol |
No published in vivo animal studies are available for Tazofelone. For research use, a rat model of inflammatory bowel disease (e.g., 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis) can be used. Male Wistar rats receive an intrarectal instillation of TNBS (30 mg in 50% ethanol) to induce colitis. Tazofelone is administered orally at doses of 3-30 mg/kg daily for 7 days. Disease activity index (weight loss, stool consistency, bleeding) is scored daily. At termination, colonic tissues are harvested for histopathological analysis (H&E staining), myeloperoxidase (MPO) activity measurement, and PGE2 levels by ELISA.
|
| ADME/Pharmacokinetics |
Tazofelone has a molecular weight of 321.48 g/mol and a formula of C18H27NO2S. It is a small lipophilic molecule (LogP ~4.0). Conversion of tazofelone to its sulfoxide and quinoline metabolites is primarily mediated by CYP3A, indicating that its pharmacokinetics may be subject to drug-drug interactions with CYP3A modulators. Detailed PK parameters (half-life, oral bioavailability) are not publicly available.
|
| Toxicity/Toxicokinetics |
As a COX-2 selective inhibitor, it may suggest a risk of cardiovascular adverse effects similar to other coxibs in clinical trials, but no clear organ toxicity has been reported. The risk of gastrointestinal ulcer formation is considered lower than that of non-selective NSAIDs. At high doses, there is a potential for nephrotoxicity and edema.
|
| References |
[1]. Leopold Franz Goetze,et al. Cox- ii inhibitors for improving reproductive success in a female animal. Patent: WO2007129169 A2.
[2]. Surapaneni SS, et al. In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone. Drug Metab Dispos. 1997 Dec;25(12):1383-8. |
| Additional Infomation |
Tazofelone (LY 213829)は炎症性腸疾患（クローン病、潰瘍性大腸炎）の治療薬として臨床試験で評価されましたが、現在は承認されていません。研究用化合物として、COX-2選択的阻害作用とその腸管炎症における役割を研究するためのツールとして利用可能です。この製品は研究用のみであり、ヒト治療用ではありません。
|
| Molecular Formula |
C18H27NO2S
|
|---|---|
| Molecular Weight |
321.48
|
| Exact Mass |
321.176
|
| CAS # |
107902-67-0
|
| PubChem CID |
68745
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.047
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1NCSC1CC1C=C(C(C)(C)C)C(O)=C(C(C)(C)C)C=1
|
| InChi Key |
ILMMRHUILQOQGP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H27NO2S/c1-17(2,3)12-7-11(9-14-16(21)19-10-22-14)8-13(15(12)20)18(4,5)6/h7-8,14,20H,9-10H2,1-6H3,(H,19,21)
|
| Chemical Name |
5-[(3,5-ditert-butyl-4-hydroxyphenyl)methyl]-1,3-thiazolidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (311.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1106 mL | 15.5531 mL | 31.1061 mL | |
| 5 mM | 0.6221 mL | 3.1106 mL | 6.2212 mL | |
| 10 mM | 0.3111 mL | 1.5553 mL | 3.1106 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
